Ono Pharmaceutical Co. (OTCMKTS:OPHLF) Short Interest Update

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 1,994,790 shares, an increase of 98.7% from the May 31st total of 1,003,767 shares. Currently, 0.4% of the shares of the stock are sold short. Based on an average daily volume of 3 shares, the days-to-cover ratio is currently 664,930.0 days.

Analysts Set New Price Targets

Separately, Zacks Research raised Ono Pharmaceutical to a “hold” rating in a report on Friday, April 17th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Ono Pharmaceutical currently has a consensus rating of “Hold”.

Ono Pharmaceutical Price Performance

OTCMKTS OPHLF remained flat at $13.50 during trading hours on Thursday. The company’s stock had a trading volume of 32 shares, compared to its average volume of 30. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.56 and a current ratio of 3.02. The firm has a 50-day moving average price of $14.38 and a 200 day moving average price of $14.58. Ono Pharmaceutical has a twelve month low of $9.20 and a twelve month high of $18.67. The firm has a market cap of $6.34 billion, a P/E ratio of 13.64 and a beta of 0.34.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research?based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.